Attached files
file | filename |
---|---|
8-K - 8-K - Vitae Pharmaceuticals, Inc | a15-20464_18k.htm |
Exhibit 99.1
Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors
Charles W. Newhall, III steps down from board
FORT WASHINGTON, PA, September 30, 2015 Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Karen Bernstein, Ph.D., to its board of directors, effective immediately. Dr. Bernstein is best known for co-founding and shaping BioCentury Publications Inc. into one of the biotechnology sectors most highly regarded sources of global industry intelligence. Dr. Bernstein stepped down from her role as Editor-in-Chief in August, but continues to serve as BioCenturys Chairman.
Karens vast professional network, industry insight, and strategic perspective will be of great value to the Vitae team as we continue to advance our wholly owned product candidates through the clinic, said Don Hayden, Chairman of Vitaes board of directors.
Dr. Bernstein co-founded BioCentury in 1992. During her tenure as Chairman and Editor-in-Chief, she was instrumental in growing the company into a key source of independent intelligence and analysis for a global biopharmaceutical audience.
Vitaes first-in-class RORyt inhibitor is a fascinating oral target in the dynamic field of immunology, said Dr. Bernstein. The Companys clinical pipeline of novel drug candidates has the potential to vastly improve the quality of life for patients afflicted with serious autoimmune disorders and inflammatory skin conditions. I look forward to working closely with Vitaes management team.
In addition to joining Vitaes board of directors, Dr. Bernstein is also on the board of Ovid Therapeutics. She currently serves as a trustee of the Keck Graduate Institute of the Applied Life Sciences and is a member of the Keck Graduate Institute School of Pharmacys board of advisors. Dr. Bernstein earned a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University.
Additionally, Vitae announced that Charles W. Newhall, III has stepped down from his role on the Companys board of directors.
I would like to thank Chuck for the insights, guidance and support he provided throughout his long-standing tenure on Vitaes board, added Mr. Hayden.
Vitae Pharmaceuticals, Inc. |
|
Tel: (215) 461-2000 |
502 West Office Center Drive |
|
Fax: (215) 461-2006 |
Fort Washington, PA 19034 |
|
www.vitaepharma.com |
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing first-in-class, small molecule drugs for difficult-to-drug disease targets that can potentially address significant unmet medical needs, including programs in autoimmune disorders, atopic dermatitis, Alzheimers disease and diabetes. This robust and growing portfolio of novel product candidates is generated internally by Contour®, Vitaes proprietary structure-based drug discovery platform.
For additional information, please visit the companys website at www.vitaepharma.com.
About BioCentury
Founded in 1992 by Karen Bernstein and David Flores, BioCentury is one of the benchmark sources of biopharma industry intelligence for a global audience of biotech and pharmaceutical executives, investors, regulators, and public policy influencers, with the goal of delivering the essential clinical, regulatory, and finance news shaping the biotechnology and pharmaceutical industries.
For additional information, please visit the companys website at www.biocentury.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended including statements regarding the clinical development of VTP-43742. In some cases, you can identify forward-looking statements by terms such as may, might, will, objective, intend, should, could, can, would, expect, believe, anticipate, project, target, design, estimate, predict, potential, plan, impending or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vitae is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vitaes forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Vitae and its collaborative partners; the ability to obtain and maintain regulatory approval of Vitaes product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Vitaes product candidates; the size and growth of the potential markets for Vitaes product candidates and the ability to serve those markets; Vitaes expectations regarding Vitaes expenses and revenue, the sufficiency of Vitaes cash resources and needs for additional financing; Vitaes ability to attract or retain key personnel; and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Vitaes Annual Report on Form 10-K for the year ended December 31, 2014 and Vitaes Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 which have been filed with the Securities and Exchange Commission (SEC). In addition to the risks described above and in Vitaes other filings with the
SEC, other unknown or unpredictable factors also could affect Vitaes results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vitae undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
###
INVESTORS:
Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
rmorris@vitaerx.com
Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com
MEDIA:
6 Degrees PR
Tony Plohoros
(908) 591-2839
tplohoros@6degreespr.com